Paul Kelly - Apr 4, 2022 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Role
Director
Signature
/s/ Paul Kelly
Stock symbol
RLMD
Transactions as of
Apr 4, 2022
Transactions value $
-$267,995
Form type
4
Date filed
4/5/2022, 05:34 PM
Previous filing
Jan 5, 2022
Next filing
Dec 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLMD Common Stock Options Exercise $32.4K +10K +5.34% $3.24 197K Apr 4, 2022 Direct
transaction RLMD Common Stock Sale -$300K -10K -5.07% $30.04* 187K Apr 4, 2022 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLMD Options to purchase common stock Options Exercise $0 -10K -32.79% $0.00 20.5K Apr 4, 2022 Common Stock 10K $3.24 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.
F2 The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
F3 Sales prices range from $30.00 to $30.20 per share, inclusive.
F4 The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.